Aegerion Pharma (AEGR) Misses Q2 EPS by 34c

Aegerion Pharma (NASDAQ: AEGR) reported Q2 EPS of ($0.72), $0.34 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $44.5 million versus the consensus estimate of $35.5 million.

For earnings history and earnings-related data on Aegerion Pharma (AEGR) click here.

You May Also Be Interested In

• Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
• Philip Morris (PM) beats Q1 earnings, revenue estimates; issues upbeat guidance
• Ryder System (R) Tops Q1 EPS by 43c